Published in Cancer Weekly, November 11th, 2003
The funding will be used to complete ongoing phase II clinical trials and initiate a pivotal phase III clinical trial program evaluating the company's lead candidate vaccine, FavId, in combination with Rituxan for the treatment of low-grade or follicular non-Hodgkin lymphoma (NHL).
"Favrille's ability to raise this funding at favorable terms, despite the current economic environment, demonstrates the enormous potential...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.